Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Zaeem Noman

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Frontiers in Oncology|December 6, 2016
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst FacetElodie Viry, Muhammad Zaeem Noman, Tsolère Arakelian, et al.
Critical Reviews in Oncogenesis|October 13, 2018
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the ShotsMalina Xiao, Muhammad Zaeem Noman, Ludovic Menard, et al.
Frontiers in Immunology|December 2, 2022
The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentationMuhammad Zaeem Noman, Irene Adelaide Bocci, Manale Karam, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2011
Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cellsMeriem Hasmim, Muhammad Zaeem Noman, Jessica Lauriol, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2017
Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L PromoterMeriem Hasmim, Bassam Janji, Mehdi Khaled, et al.
Oncoimmunology|February 16, 2017
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200Muhammad Zaeem Noman, Bassam Janji, Abderemane Abdou, et al.
Oncoimmunology|April 18, 2025
Targeting the atypical chemokine receptor 2 (<i>Ackr2</i>) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse modelMuhammad Zaeem Noman, Martyna Szpakowska, Malina Xiao, et al.
Oncoimmunology|March 28, 2017
Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicityStéphane Terry, Stéphanie Buart, Tuan Zea Tan, et al.
Cells|June 21, 2019
The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor MicroenvironmentNathan Reynders, Dayana Abboud, Alessandra Baragli, et al.
Cancer Letters|May 29, 2019
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpointsAudrey Lequeux, Muhammad Zaeem Noman, Malina Xiao, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|December 6, 2016
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst FacetElodie Viry, Muhammad Zaeem Noman, Tsolère Arakelian, et al.
Critical Reviews in Oncogenesis|October 13, 2018
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the ShotsMalina Xiao, Muhammad Zaeem Noman, Ludovic Menard, et al.
Frontiers in Immunology|December 2, 2022
The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentationMuhammad Zaeem Noman, Irene Adelaide Bocci, Manale Karam, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2011
Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cellsMeriem Hasmim, Muhammad Zaeem Noman, Jessica Lauriol, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2017
Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L PromoterMeriem Hasmim, Bassam Janji, Mehdi Khaled, et al.
Oncoimmunology|February 16, 2017
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200Muhammad Zaeem Noman, Bassam Janji, Abderemane Abdou, et al.
Oncoimmunology|April 18, 2025
Targeting the atypical chemokine receptor 2 (<i>Ackr2</i>) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse modelMuhammad Zaeem Noman, Martyna Szpakowska, Malina Xiao, et al.
Oncoimmunology|March 28, 2017
Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicityStéphane Terry, Stéphanie Buart, Tuan Zea Tan, et al.
Cells|June 21, 2019
The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor MicroenvironmentNathan Reynders, Dayana Abboud, Alessandra Baragli, et al.
Cancer Letters|May 29, 2019
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpointsAudrey Lequeux, Muhammad Zaeem Noman, Malina Xiao, et al.
Pageof 6